Manufacturer
NOVARTIS PHARMA PRODUKTIONS GMBH
Contents
Per 50 mg/850 mg FC tab Vildagliptin 50 mg, metformin HCl 850 mg.
Indication
Type 2 DM inadequately controlled on metformin alone or who are already treated w/ combination of vildagliptin & metformin as separate tab. In triple combination therapy w/ sulphonylurea as an adjunct to diet & exercise in patients inadequately controlled w/ metformin & sulphonylurea. In triple combination therapy w/ insulin as an adjunct to diet & exercise to improve glycaemic control in adult patients when stable dose of insulin & metformin alone do not provide adequate glycaemic control. Initial therapy in patients w/ type 2 DM whose diabetes is inadequately controlled by diet & exercise alone.
Instruction
Should be taken with food: Take w/ or immediately after meals to reduce GI discomfort.
Drug interaction
Vildagliptin: Increased risk of angioedema w/ ACE inhibitors. Reduced hypoglycaemic effect w/ thiazides, corticosteroids, thyroid products & sympathomimetics. Metformin: Increased risk of lactic acidosis in acute alcohol intoxication. Increased systemic exposure w/ cimetidine. Intrinsic hyperglycaemic activity w/ glucocorticoids, β2-agonists & diuretics. Decreased blood glucose levels w/ ACE inhibitors.
Malaysia
